背景:免疫治疗是治疗广泛小细胞肺癌(ES-SCLC)的转折点。虽然,许多问题仍在辩论中。
方法:一组在管理ES-SCLC患者方面具有专业知识的意大利医学和放射肿瘤学家制定了一份陈述清单,分为六个感兴趣的领域。德尔菲法用于评估对定义的陈述列表的共识。
结果:32项声明被列入由德尔福小组投票的最终名单,26日就协议达成共识。多学科团队的迅速参与是提供综合治疗策略的优先事项。一线推荐的治疗方法是免疫疗法与铂类化疗和依托泊苷联合四个周期,然后进行维持免疫疗法。
结论:在等待临床试验和现实世界研究的新数据时,这些建议可以成为在日常实践中指导ES-SCLC患者管理的有用工具.
BACKGROUND: Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-
SCLC). Although, many issues remain debated.
METHODS: A group of Italian medical and radiation oncologists with expertise in managing patients with ES-
SCLC developed a list of statements divided in six areas of interest. The Delphi method was used to assess the
consensus on the defined list of statements.
RESULTS: 32 statements were included in the final list to be voted by the Delphi panel, and 26 reached a
consensus on the agreement. A prompt involvement of a multidisciplinary team is a priority to provide an integrated treatment strategy. First-line recommended treatment is immunotherapy in combination with platinum-based chemotherapy and etoposide for four cycles followed by maintenance immunotherapy.
CONCLUSIONS: While awaiting new data from clinical trials and real-world studies, these recommendations can represent a useful tool to guide the management of ES-
SCLC patients in daily practice.